**Supplementary Appendix**

**FIGURES**

[**Supplemental Figure S1.** Physician’s caseload](#first)

[**Supplemental Figure S2.** Physician’s perception of importance of JAK2 V617F mutation testing and bone marrow biopsy for diagnosing MPN](#Second)

[**Supplemental Figure S3.** Physician’s perception of proportion of symptomatic MPN patients that undergo diagnostic testing](#Third)

[**Supplemental Figure S4.** Physician’s perception of top reasons why symptomatic MPN patients do not undergo JAK2 V617F testing](#four)

[**Supplemental Figure S5.** Physician’s perception of top reasons why symptomatic MPN patients do not undergo bone marrow biopsy testing](#five)

[**Supplemental Figure S6.** Physician perception of MF disease burden](#six)

[**Supplemental Figure S7.** Physician perception of MF patient’s symptoms at first visit vs currently](#seve)

[**Supplemental Figure S8.** Physician perception of top MF symptoms](#eig)

[**Supplemental Figure S9.** Physician perception of MF symptoms’ impact on quality of life](#nin)

[**Supplemental Figure S10.** Physician perception of MF patient concerns – functional and financial well-being](#ten)

[**Supplemental Figure S11.** Physician perception ofMF patient concerns – physical, social/ family well-being](#ele)

[**Supplemental Figure S12.** Physician perception of MF disease progression](#twel)

[**Supplemental Figure S13.** Physician perception of patient involvement in treatment decisions](#thirt)

[**Supplemental Figure S14.** Physician perception of patient and physician alignment on treatment goals](#fourt)

[**Supplemental Figure S15.** Physician perception of factors used to assess MF progression](#fift)

[**Supplemental Figure S16.** Physician perception of MF symptoms most likely to be recommended a drug](#sixteen)

[**Supplemental Figure S17.** Physician perception of treatment goals for MF patients](#sevent)

[**Supplemental Figure S18.** Physician perception for patient reasons for changing drug therapy of MF patients](#eighte)

[**Supplemental Figure S19.** Physician perception of solutions to overcoming unmet needs in MF](#ninent)

Physician’s caseload

**S****upplemental Figure S1.** Physician’s caseload



Diagnostic challenges of MPN

**Supplemental Figure S2.** Physician’s perception of importance of JAK2 V617F mutation testing and bone marrow biopsy for diagnosing MPN

**Supplemental Figure S3.** Physician’s perception of proportion of symptomatic MPN patients that undergo diagnostic testing

****

**Supplemental Figure S4.** Physician’s perception of top reasons why symptomatic MPN patients do not undergo JAK2 V617F testing

****

**Supplemental Figure S5.** Physician’s perception of top reasons why symptomatic MPN patients do not undergo bone marrow biopsy testing

****

MF disease burden

**Supplemental Figure S6.** Physician perception of MF disease burden



**Supplemental Figure S7.** Physician perception of MF patient’s symptoms at first visit vs currently



**Supplemental Figure S8.** Physician perception of top MF symptoms

**Supplemental Figure S9.** Physician perception of MF symptoms’ impact on quality of life



**Supplemental Figure S10.** Physician perception of MF patient concerns – functional and financial well-being

% Haematologist-Medical Oncologists

% Haematologist-Medical Oncologists



**Supplemental Figure S11.** Physician perception ofMF patient concerns – physical, social/ family well-being



**Supplemental Figure S12.** Physician perception of MF disease progression



Shared decision making

**Supplemental Figure S13.** Physician perception of patient involvement in treatment decisions

****

**Supplemental Figure S14.** Physician perception of patient and physician alignment on treatment goals

 



% Haematologist-Medical Oncologists

MF treatment

**Supplemental Figure S15.** Physician perception of factors used to assess MF progression



**Supplemental Figure S16.** Physician perception of MF symptoms most likely to be recommended a drug 

**Supplemental Figure S17.** Physician perception of treatment goals for MF patients ****

% Haematologist-Medical Oncologists

**Supplemental Figure S18.** Physician perception for patient reasons for changing drug therapy of MF patients



Unmet needs

**Supplemental Figure S19.** Physician perception of solutions to overcoming unmet needs in MF

